25
https://pubmed.ncbi.nlm.nih.gov/38114518
The study found that neoadjuvant durvalumab plus radiation or durvalumab alone had similar disease-free survival rates in stages I-III non-small cell lung cancer, and explored potential biomarkers of response and recurrence.